Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma

Journal of Neuro-Oncology

Volumn 103, Issue 1, 2011, Pages 19-31

  Matsuda, Masahide ^a,b   Nimura, Keisuke ^a   Shimbo, Takashi ^a   Hamasaki, Toshimitsu ^c   Yamamoto, Tetsuya ^b   Matsumura, Akira ^b   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

HVJ envelope; Immunogene therapy; Interleukin 2; Malignant glioma; Regulatory T cell

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; FIREFLY LUCIFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; PLASMID VECTOR; PRAINFLUENZA VIRUS 1 ENVELOPE VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRADERMAL TUMOR; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MITOSIS RATE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARAINFLUENZA VIRUS 1; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR; TUMOR IMMUNITY; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN NEOPLASMS; CYTOKINES; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; GLIOMA; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; ONCOLYTIC VIROTHERAPY; SENDAI VIRUS; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 79960022868     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0355-x     Document Type: Article

References (49)

1. Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg 99:458-466 (Pubitemid 37040404)
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
3. Yang L, Ng KY, Lillehei KO (2003) Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10:138-147 (Pubitemid 36437820)
4. Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253-1265 (Pubitemid 46622028)
5. Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58-69
6. Fabry Z, Raine CS, Hart MN (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 15:218-224 (Pubitemid 24137975)
7. Frei K, Fontana A (1997) Antigen presentation in the CNS. Mol Psychiatry 2:96-98 (Pubitemid 27166020)
8. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3:569-581 (Pubitemid 37328676)
9. Shrikant P, Benveniste EN (1996) The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. J Immunol 157:1819-1822 (Pubitemid 126449650)
10. El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8: 234-243 (Pubitemid 46542648)
11. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ (2007) CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121:95-105 (Pubitemid 46753856)
12. Kurooka M, Kaneda Y (2007) Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67:227-236 (Pubitemid 46142779)
13. Fujihara A, Kurooka M, Miki T, Kaneda Y (2008) Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 57:73-84 (Pubitemid 350043650)
14. Kawano H, Komaba S, Kanamori T, Kaneda Y (2007) A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Med 5:28
15. Kawano H, Komaba S, Yamasaki T, Maeda M, Kimura Y, Maeda A, Kaneda Y (2008) New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemother Pharmacol 61:973-978 (Pubitemid 351423124)
16. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H (2002) Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6:219-226 (Pubitemid 36336129)
17. Kaneda Y (2003) New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 4:599-602 (Pubitemid 37236374)
18. Kaneda Y, Yamamoto S, Nakajima T (2005) Development of HVJ envelope vector and its application to gene therapy. Adv Genet 53:307-332 (Pubitemid 43580672)
19. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7:1044-1052 (Pubitemid 41195066)
20. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y (2006) Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatinconjugated HVJ envelope vector. Mol Cancer Ther 5:1021-1028 (Pubitemid 43724603)
21. Lefranc F, Cool V, Velu T, Brotchi J, De Witte O (2002) Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 20:1077-1085
22. Pan D, Wei X, Liu M, Feng S, Tian X, Feng X, Zhang X (2009) Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells. Neurol Res. doi:10.1179/174313209X455736
23. Natsume A, Mizuno M, Ryuke Y, Yoshida J (1999) Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6:1626-1633 (Pubitemid 29465522)
24. Meijer DH, Maguire CA, LeRoy SG, Sena-Esteves M (2009) Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 16:664-671
25. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP (1999) Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45:867-874 (Pubitemid 29467815)
26. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11:1155-1164 (Pubitemid 39117311)
27. Iwadate Y, Inoue M, Saegusa T, Tokusumi Y, Kinoh H, Hasegawa M, Tagawa M, Yamaura A, Shimada H (2005) Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 11:3821-3827 (Pubitemid 40685602)
28. Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villarreal LP, Black KL, Yu JS (2002) In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9:9-15 (Pubitemid 34052849)
29. Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY (2005) Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 7:213-224 (Pubitemid 41079131)
30. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523-532
31. Sonabend AM, Rolle CE, Lesniak MS (2008) The role of regulatory T cells in malignant glioma. Anticancer Res 28:1143-1150 (Pubitemid 351578852)
32. Lieschke GJ, Rao PK, Gately MK, Mulligan RC (1997) Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 15:35-40
33. Foss DL, Moody MD, Murphy KP Jr, Pazmany C, Zilliox MJ, Murtaugh MP (1999) In vitro and in vivo bioactivity of singlechain interleukin-12. Scand J Immunol 50:596-604
34. Bello L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Tomei G, Villani R, Scaglione F, Carroll RS, Bikfalvi A (2002) Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 8:3539-3548 (Pubitemid 35340732)
35. Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121
36. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552
37. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835-848 (Pubitemid 43086285)
38. Tamura K, Tamura M, Ikenaka K, Yoshimatsu T, Miyao Y, Nanmoku K, Shimizu K (2001) Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene. Gene Ther 8:215-22236
39. Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665-674 (Pubitemid 39223073)
40. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ (2002) Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 196:851-857
41. Rosenberg SA, Lotze MT, Mule JJ (1988) NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108:853-864
42. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415
43. El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105: 430-437 (Pubitemid 44358755)
44. Suzuki H, Kurooka M, Hiroaki Y, Fujiyoshi Y, Kaneda Y (2008) Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett 582:1325-1329
45. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells. Science 299:1033-1036 (Pubitemid 36222922)
46. Jacobs A, Clifford P, Kay HE (1981) The Ommaya reservoir in chemotherapy for malignant disease in the CNS. Clin Oncol 7:123-129 (Pubitemid 11094326)
47. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124:2478-2487
48. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y (2009) Sterile alpha motif containing domain 9 (SAMD9) is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer. doi:10.1002/ijc.24965
49. Matsuda M, Yamamoto T, Matsumura A, Kaneda Y (2009) Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Ther 16: 1465-1476